Advisor Group Inc. Purchases 11,982 Shares of Astrazeneca PLC (AZN)

Advisor Group Inc. raised its position in Astrazeneca PLC (NYSE:AZN) by 19.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,121 shares of the company’s stock after purchasing an additional 11,982 shares during the period. Advisor Group Inc.’s holdings in Astrazeneca PLC were worth $2,546,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AZN. Voya Investment Management LLC lifted its holdings in Astrazeneca PLC by 38.2% in the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after purchasing an additional 662,481 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Astrazeneca PLC by 746.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 620,901 shares of the company’s stock valued at $21,167,000 after purchasing an additional 547,512 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Astrazeneca PLC by 4.7% in the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares in the last quarter. State Street Corp purchased a new position in Astrazeneca PLC in the 2nd quarter valued at about $14,536,000. Finally, Suffolk Capital Management LLC purchased a new position in Astrazeneca PLC in the 2nd quarter valued at about $12,591,000. Institutional investors own 14.16% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/11/16/advisor-group-inc-purchases-11982-shares-of-astrazeneca-plc-azn.html.

Astrazeneca PLC (NYSE AZN) traded up $0.14 during mid-day trading on Thursday, hitting $33.39. 2,211,700 shares of the stock were exchanged, compared to its average volume of 4,829,131. Astrazeneca PLC has a twelve month low of $25.55 and a twelve month high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The firm has a market capitalization of $84,185.54, a P/E ratio of 7.94, a P/E/G ratio of 3.14 and a beta of 0.75.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the company earned $1.32 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. research analysts forecast that Astrazeneca PLC will post 1.93 EPS for the current fiscal year.

Several research analysts have recently weighed in on the stock. Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Leerink Swann increased their price objective on shares of Astrazeneca PLC from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Argus reiterated a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a report on Friday, September 1st. Credit Suisse Group upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Astrazeneca PLC currently has an average rating of “Hold” and an average target price of $34.20.

Astrazeneca PLC Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply